| Host: |
Rabbit |
| Applications: |
WB/ELISA |
| Reactivity: |
Human/Mouse |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Rabbit polyclonal antibody anti-Transcription factor Sp7 (280-360 aa) is suitable for use in Western Blot and ELISA research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
Liquid in PBS containing 50% Glycerol and 0.02% Sodium Azide. |
| Purification: |
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
| Concentration: |
1 mg/mL |
| Dilution Range: |
WB 1:500-2000ELISA 1:5000-20000 |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Gene Symbol: |
SP7 |
| Gene ID: |
121340 |
| Uniprot ID: |
SP7_HUMAN |
| Immunogen Region: |
280-360 aa |
| Specificity: |
SP7 Polyclonal Antibody detects endogenous levels of protein. |
| Immunogen: |
Synthesized peptide derived from the human protein at the amino acid range 280-360 |
| Post Translational Modifications | Ubiquitination at leads to proteasomal degradation. SP7 is a short-live protein with an endogenous half-life of approximately 12 hours. Propionylated. Depropionylation at Lys-371 by SIRT7 activates transcription factor activity and positively regulates bone formation by osteoblasts. |
| Function | Transcriptional activator essential for osteoblast differentiation. Binds to SP1 and EKLF consensus sequences and to other G/C-rich sequences. |
| Protein Name | Transcription Factor Sp7Zinc Finger Protein Osterix |
| Database Links | Reactome: R-HSA-8940973 |
| Cellular Localisation | Nucleus |
| Alternative Antibody Names | Anti-Transcription Factor Sp7 antibodyAnti-Zinc Finger Protein Osterix antibodyAnti-SP7 antibodyAnti-OSX antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
